A Phase 1, Open-Label, Single-Center, Randomized, 3-Way Crossover Study to Assess the Effect of Food on the Bioavailability of a Single Oral Dose of 80 mg Febuxostat Extended-Release Formulation and the Pharmacokinetics of a Single Oral Dose of 40 mg and 80 mg Febuxostat Extended-Release Formulation in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2016
At a glance
- Drugs Febuxostat (Primary)
- Indications Gout
- Focus Pharmacokinetics
- Sponsors Takeda
- 21 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Mar 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 04 Mar 2015 New trial record